Adjusting for tumor stage, presence of metastases, pathological state and histological grade, over-expression of ACE-2 was notably correlate with  longer overall survival (Hazard Ratio = 0.8259; 95%CI: 0.7734–0.8819; Logrank p < 0.0001) and relapse-free survival (Hazard Ratio = 0.8023; 95%CI: 0.7375–0.8729; Logrank p < 0.0001) in clear cell renal cell carcinoma patients, using TCGA, GEO and TIP database [43]. This evidence concerns the gene ACE2 and neoplasm.